Virchows Archiv,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 8, 2025
Abstract
Digital
Pathology
(DP)
revolutionizes
the
diagnostic
workflow.
Digitized
scanned
slides
enhance
operational
efficiency
by
facilitating
remote
access,
slide
storage,
reporting
and
automated
AI
image
analysis,
enabling
collaboration
research.
However,
substantial
upfront
maintenance
costs
remain
significant
barriers
to
adoption.
This
study
evaluates
DP’s
financial
qualitative
value,
exploring
whether
long-term
benefits
justify
investments
addressing
implementation
challenges
in
large
public
private
European
laboratory
settings.
A
targeted
literature
review,
semi-structured
interviews,
surveys,
a
net
present
value
(NPV)
model
were
employed
assess
impact
on
clinical
practice
financials.
Qualitative
findings
validate
key
of
DP,
including
optimized
workflow,
enhanced
logistics,
improved
organization.
Pathologists
reported
smooth
integration,
training,
teaching,
research
capabilities,
increased
flexibility
through
work.
Collaboration
within
multidisciplinary
teams
was
strengthened,
while
case
examination
access
archival
notably
improved.
Quantitative
results
indicate
that
DP
demonstrates
strong
potential,
achieving
cost
recovery
6
years.
investment
7-year
NPV
+
€0.21
million
(m)
driven
productivity
diagnosis
volumes.
Although
high
for
scanners,
system
integration
pose
barrier
adoption
larger
institutions
are
better
positioned
leverage
economies
scale.
underscores
importance
sustained
support
cope
with
initial
regional
driving
widespread
DP.
Expanding
reimbursement
policies
pathology
procedures
could
significantly
reduce
barriers.
Pharmaceuticals,
Journal Year:
2024,
Volume and Issue:
17(5), P. 652 - 652
Published: May 17, 2024
Precise
targeting
has
become
the
main
direction
of
anti-cancer
drug
development.
Trophoblast
cell
surface
antigen
2
(Trop-2)
is
highly
expressed
in
different
solid
tumors
but
rarely
normal
tissues,
rendering
it
an
attractive
target.
Trop-2-targeted
antibody-drug
conjugates
(ADCs)
have
displayed
promising
efficacy
treating
diverse
tumors,
especially
breast
cancer
and
urothelial
carcinoma.
However,
their
clinical
application
still
limited
by
insufficient
efficacy,
excessive
toxicity,
lack
biological
markers
related
to
effectiveness.
This
review
summarizes
trials
combination
therapy
strategies
for
ADCs,
discusses
current
challenges,
provides
new
insights
future
advancements.
MedComm,
Journal Year:
2024,
Volume and Issue:
5(8)
Published: July 28, 2024
Abstract
Antibody–drug
conjugates
(ADCs)
consist
of
monoclonal
antibodies
that
target
tumor
cells
and
cytotoxic
drugs
linked
through
linkers.
By
leveraging
antibodies’
targeting
properties,
ADCs
deliver
into
via
endocytosis
after
identifying
the
antigen.
This
precise
method
aims
to
kill
selectively
while
minimizing
harm
normal
cells,
offering
safe
effective
therapeutic
benefits.
Recent
years
have
seen
significant
progress
in
antitumor
treatment
with
ADC
development,
providing
patients
new
potent
options.
With
over
300
explored
for
various
indications
some
already
approved
clinical
use,
challenges
such
as
resistance
due
factors
like
antigen
expression,
processing,
payload
emerged.
review
outline
history
their
structure,
mechanism
action,
recent
composition
advancements,
selection,
completed
ongoing
trials,
mechanisms,
intervention
strategies.
Additionally,
it
will
delve
potential
novel
markers,
linkers,
payloads,
innovative
action
mechanisms
enhance
cancer
The
evolution
has
also
led
emergence
combination
therapy
a
approach
improve
drug
efficacy.
Pharmaceutics,
Journal Year:
2024,
Volume and Issue:
16(9), P. 1146 - 1146
Published: Aug. 29, 2024
The
advent
of
immunotherapy
and
antibody–drug
conjugates
(ADCs)
have
revolutionized
breast
cancer
treatment,
offering
new
hope
to
patients.
However,
challenges,
such
as
resistance
limited
efficacy
in
certain
cases,
remain.
Recently,
the
combination
these
therapies
has
emerged
a
promising
approach
address
challenges.
ADCs
play
crucial
role
by
delivering
cytotoxic
agents
directly
cells,
minimizing
damage
healthy
tissue
enhancing
tumor-killing
effect.
Concurrently,
immunotherapies
harness
body’s
immune
system
recognize
eliminate
cells.
This
integration
offers
potential
overcome
mechanisms
significantly
improve
therapeutic
outcomes.
review
explores
rationale
behind
combining
with
ADCs,
recent
advances
this
field,
implications
for
treatment.
Expert Opinion on Pharmacotherapy,
Journal Year:
2024,
Volume and Issue:
25(6), P. 727 - 742
Published: April 12, 2024
The
introduction
of
targeted
therapy
and
immunotherapy
has
tremendously
changed
the
clinical
outcomes
prognosis
cancer
patients.
Despite
innovative
pharmacological
therapies
improved
radiotherapy
(RT)
techniques,
patients
continue
to
suffer
from
side
effects,
which
oral
mucositis
(OM)
is
still
most
impactful,
especially
for
quality
life.
We
provide
an
overview
current
advances
in
pharmacotherapy
RT,
relation
their
potential
cause
OM,
less
explored
more
recent
literature
reports
related
best
management
OM.
have
analyzed
natural/antioxidant
agents,
probiotics,
mucosal
protectants
healing
coadjuvants,
pharmacotherapies,
immunomodulatory
anticancer
photobiomodulation
impact
technology.
discovery
precise
pathophysiologic
mechanisms
CT
RT-induced
OM
outlined
that
a
multifactorial
origin,
including
direct
oxidative
damage,
upregulation
immunologic
factors,
effects
on
flora.
A
persistent
upregulated
immune
response,
associated
with
factors
patients'
characteristics,
may
contribute
severe
long-lasting
goal
strategies
conjugate
individual
patient,
disease,
therapy-related
guide
prevention
or
treatment.
further
high-quality
research
warranted,
issue
paramount
future
strategies.
BJU International,
Journal Year:
2024,
Volume and Issue:
134(4), P. 615 - 621
Published: June 19, 2024
Objective
To
evaluate
the
potential
utility
of
antibody‐drug
conjugates
targeting
trophoblast
cell
surface
antigen‐2
(TROP‐2)
in
patients
with
primary
penile
squamous
carcinoma
(PSCC),
recurrence
(REC
cohort),
and
patient‐matched
distant
metastases
(MET
to
assess
use
TROP‐2
as
a
predictive
non‐invasive
biomarker
PSCC.
Methods
A
cohort
comprising
PRIM
(
n
=
37),
REC
5)
MET
subcohort
7),
including
lymph
node
lung
metastases,
was
analysed
using
quantitative
real‐time
PCR,
ELISA
immunohistochemical
staining
evaluation
H‐score.
Results
mRNA
serum
protein
levels
were
significantly
increased
recurrent
PSCC
compared
cancer‐free
controls
(both
P
<
0.001).
Immunohistochemical
analysis
revealed
that
most
34/37,
median
H‐score
260,
interquartile
range
[IQR]
210–300),
well
all
(median
200
[165–290])
cohorts
280
[260–300])
exhibited
moderate
strong
membranous
expression.
Additionally,
The
(membranous
expression)
positively
correlated
ρ
0.69,
0.0001,
R
2
0.70)
0.86,
0.59),
indicating
its
Conclusion
In
summary,
our
results
support
further
studies
on
diagnostic
therapeutic
target
primary,
metastatic
International Journal of Gynecological Cancer,
Journal Year:
2024,
Volume and Issue:
34(11), P. 1795 - 1804
Published: July 29, 2024
Clinical
outcomes
remain
challenging
in
advanced
or
recurrent
endometrial
cancer
due
to
tumor
heterogeneity
and
therapy
resistance.
Antibody-drug
conjugates
are
a
novel
class
of
therapeutics,
representing
promising
treatment
option
for
cancer.
consist
high-affinity
antibody
linked
cytotoxic
payload
through
stable
linker.
After
binding
specific
antigens
on
cells,
the
drug
is
internalized,
released.
In
addition,
free
intracellular
may
be
released
outside
target
cell
'bystander
effect'
kill
neighboring
which
crucial
treating
malignancies
characterized
by
heterogeneous
biomarker
expression
like
This
article
aims
provide
comprehensive
overview
current
clinical
landscape
antibody-drug
We
conducted
thorough
analysis
recent
trials
focusing
efficacy,
safety
profiles,
mechanisms
focused
particularly
most
conjugate
targets
under
investigation,
such
as
human
epidermal
growth
factor
receptor
2
(HER2),
folate
alpha
(FRα),
trophoblast
cell-surface
antigen-2
(TROP2),
B7-H4.
also
briefly
comment
challenges,
including
emergence
resistance
mechanisms,
future
development
directions
(especially
agents
targeting
multiple
antigens,
combinatorial
strategies,
sequential
use
same
antigen
but
using
different
payloads)
Scientific Reports,
Journal Year:
2024,
Volume and Issue:
14(1)
Published: Jan. 4, 2024
Abstract
Distinguishing
indolent
from
clinically
significant
localized
prostate
cancer
is
a
major
clinical
challenge
and
influences
decision-making
between
treatment
active
surveillance.
The
development
of
novel
predictive
biomarkers
will
help
with
risk
stratification,
decision-making,
leading
to
decrease
in
over
or
under-treatment
patients
cancer.
Here,
we
report
that
Trop2
prognostic
tissue
biomarker
for
by
utilizing
the
Canary
Prostate
Cancer
Tissue
Microarray
(CPCTA)
cohort
composed
1100
multi-institutional
study.
We
demonstrate
elevated
expression
correlated
worse
features
including
Gleason
score,
age,
pre-operative
PSA
levels.
More
importantly,
at
radical
prostatectomy
predicts
overall
survival
men
undergoing
prostatectomy.
Additionally,
detect
shed
urine
Our
study
identifies
as
candidate
non-invasive
marker